Zhejiang Sunflower Great Health Co., Ltd. (ZHEJIANG SUNFLOWER GREAT HEALTH) Aktie

Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pneumonia, and urethritis and cervicitis; and azithromycin dispersible tablets and injections for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection. The company also provides roxithromycin capsules to treat pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, acute exacerbation, as well as urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for the treatment of high blood pressure; and simvastatin tablets used for hyperlipidemia, coronary heart disease combined with hypercholesterolemia, and children with heterozygous familial hypercholesterolemia. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; and famotidine for injection for treatment of peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.